H5N1 Antibodies

Recent developments in the spread of the H5N1 avian influenza (commonly known as bird flu) virus have raised global concerns, marking a significant shift in the virus's epidemiology. Initially identified over two decades ago, H5N1, a strain of highly pathogenic avian influenza (HPAI), has undergone substantial genetic changes, enhancing its pathogenicity and expanding its host range. Notably, the virus has demonstrated the capability to infect a wide array of avian species and mammals, including humans, posing a potential risk of a future pandemic.¹

In light of these developments, research efforts have intensified to understand the molecular mechanisms of H5N1 pathogenicity and transmissibility. A critical area of focus is the hemagglutinin (HA) protein, a major surface antigen of the influenza virus that mediates entry into host cells. Rockland's advanced suite of antibodies against the H5N1 HA protein offers a vital tool for scientists aiming to map the antigenic landscape of H5N1 and develop strategies for both therapeutic interventions and vaccines.

Figure. Schematic representation of an influenza A virus (Adapted from Eichberg et al., 2022)